Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion

Journal of Hepatology

Volumn 30, Issue 1, 1999, Pages 156-160

  Chariot, Patrick ^a,b   Drogou, Irène ^b   Lacroix Szmania, Isabelle De ^a   Eliezer Vanerot, Marie Christine ^b   Chazaud, Bénédicte ^b   Lombès, Anne ^c   Schaeffer, Annette ^a   Zafrani, Elie Serge ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

HIV; Lactic acidosis; Liver; Mitochondria; Mitochondrial DNA; Skeletal muscle; Steatosis; Zidovudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DIDANOSINE; MITOCHONDRIAL DNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DNA DETERMINATION; DRUG INDUCED DISEASE; FATTY LIVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIVER BIOPSY; MALE; MITOCHONDRIAL MYOPATHY; MYOPATHY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE;

EID: 0032897185     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80020-8     Document Type: Article

References (41)

1. The Delta Coordinating Committee: Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 348:1996;283-291.
2. Hammer S. Advances in an antiretroviral therapy and viral load monitoring. AIDS. 10:((suppl 3)):1996;S1-S11.
3. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3′-azido-2′3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 321:1989;726-738.
4. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1:1995;417-422.
5. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 39:1991;625-628.
6. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′,3′dideoxyinosine (ddI). Ann Intern Med. 115:1991;283-284.
7. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med. 235:1994;367-372.
8. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine trearment in an HIV patient: a case report. AIDS. 11:1997;1294-1296.
9. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B infection. N Engl J Med. 333:1995;1099-1105.
10. Semino-Mora C, Leon-Monzon M, Dalakas MC. Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro. Lab Invest. 76:1997;487-495.
11. Lewis W, Levine ES, Grinuviene B, Tankersley KO, Colacino JM, Sommadossi JP, et al. Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA. 93:1996;3592-3597.
12. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 322:1990;1098-1105.
13. Mhiri C, Baudrimont M, Bonne G, Geny C, Degoul F, Marsac C, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol. 29:1991;606-614.
14. Chariot P, Gherardi R. Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopathy. Neuromusc Disord. 1:1991;357-363.
15. Tomelleri G, Tonin P, Spadaro M, Tilia G, Orrico D, Barelli A, et al. AZT-induced mitochondrial myopathy. Ital J Neurol Sci. 13:1992;723-728.
16. Chariot P, Monnet I, Mouchet M, Rohr M, Lefaucheur JP, Dubreuil-Lemaire ML, et al. Blood lactate/pyruvate ratio as a non invasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum. 37:1994;583-586.
17. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 337:1991;508-510.
18. Chattha G, Arieff AL, Cummings C, Tierney LM. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med. 118:1993;37-39.
19. Maslo C, Jacomet C, Jupas JJ, Lebrette MG, Rozenbaum W. Acidose lactique chez des patients infectés par le VIH. Presse Med. 23:1994;717.
20. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS. 7:1993;379-385.
21. Le Bras P, D'Oiron R, Quertainmont Y, Halfon P, Caquet R. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? AIDS. 8:1994;716-717.
22. Olano JP, Borucki MJ, Wen JW, Haque AK. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis. 21:1995;973-976.
23. Dubin G, Braffman MN. Zidovudine-induced hepatotoxicity. Ann Intern Med. 110:1989;85-86.
24. Gradon JD, Chapnick EK, Sepkowitz DV. Zidovudine-induced hepatitis. J Intern Med. 231:1992;317-318.
25. Chen SCA, Barker SM, Mitchell DH, Stevens SMB, O'Neill P, Cunningham AL. Concurrent zidovudine-induced myopathy and hepatotoxicity in patients treated for HIV infection. Pathology. 24:1992;109-111.
26. Fortgang I, Belitsos P, Chaisson R, Moore R. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol. 90:1995;1433-1436.
27. Chariot P, Monnet I, Gherardi R. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy. Ann Neurol. 34:1993;561-565.
28. Drouin J. Cloning of human mitochondrial DNA in Escherichia coli. J Mol Biol. 140:1980;15-34.
29. Gonzalez IL, Gorski JL, Campen TJ, Dorney DJ, Erickson JM, Sylvester JE, et al. Variation among human 28S ribosomal RNA genes. Proc Natl Acad Sci USA. 82:1985;7666-7670.
30. Canas E, Pachon J, Garcia-Pesquena F, Castillo JR, Villana P, Cisneros JM, et al. Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 40:1996;230-233.
31. Lamperth L, Dalakas MC, Dagani F, Anderson J, Ferrari R. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Lnvest. 65:1991;742-751.
32. Corcuera T, Alonso MJ, Picazo A, Gomez F, Roldan M, Abad M, et al. Hepatic morphological alterations induced by zidovudine in an experimental model. Pathol Res Pract. 192:1996;182-187.
33. Benbrik E, Chariot P, Bonavaud S, Ammi-Saïd M, Rey C, Gherardi R, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci. 149:1997;19-25.
34. Bioulac-Sage P, Parrot-Roulaud F, Mazat JP, Lamireau T, Coquet M, Sandler B, et al. Fatal neonatal liver failure and mitochondrial cytopathy (oxidative phosphorylation deficiency); a light and electron microscopic study of the liver. Hepatology. 18:1993;839-845.
35. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol. 26:((suppl 1)):1997;13-22.
36. Poggi-Travert F, Martin D, Billette de Villemeur T, Bonnefont JP, Vassault A, Rabier D, et al. Metabolic intermediates in lactic acidosis: compounds, samples and interpretation. J Inter Metab Dis. 19:1996;478-488.
37. Hammans SR, Morgan-Hughes JA. Mitochondrial myopathies: clinical features, investigation, treatment and genetic counselling. Di Mauro S, Schapira AHV, . Mitochondrial Disorders in Neurology. 1994;49-74 Butterworth-Heinemann, Oxford.
38. Moraes C, Shanske SE, Tritschler HJ, Aprille JR, Andreetta F, Bonilla E, et al. MtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet. 48:1991;492-501.
39. Casademont J, Barrientos A, Gruau JM, Pedrol E, Estivilli X, Urbano-Marquez A, et al. The effects of zidovudine on skeletal muscle mt-DNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain. 119:1996;1357-1364.
40. Herskowitz A, Sharon B, Baughman K, Schulman S, Bartlett J. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med. 116:1992;311-313.
41. Munnich A, Rötig A, Chrétien D, Cormier V, Bourgeron T, Bonnefont JP, et al. Clinical presentation of mitochondrial disorders in childhood. J Inher Metab Dis. 19:1996;521-527.